Edity Therapeutics
Using Human Immune Cells to Deliver Therapeutic Proteins
Company Overview
Snapshot
Founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster, Edity Therapeutics operates with 11–50 employees. The company has raised $13.63 million across 3 funding rounds from 7 investors. In January 2024, Edity Therapeutics entered a strategic collaboration with Dr. Reddy's Laboratories.
Business overview
Edity Therapeutics is a Health Tech & Life Sciences company focused on developing a platform that utilizes the immune system to deliver therapeutic proteins directly into target cells. This technology aims to reprogram cells and tissues to health by changing disease at the intracellular level through mechanisms like protein replacement, target modulation, genetic correction, and protein gain of function. The company is currently developing programs in oncology and genetic disease, with future plans for regeneration and longevity.
Strategic signal
In January 2024, Edity Therapeutics announced a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach, leveraging Edity's proprietary delivery platform. This partnership with a major pharmaceutical company signals significant external validation of Edity's technology and its potential to impact the development of new therapeutic modalities, particularly in areas like oncology and genetic diseases.
Log in to access full profile ›Company Intelligence Q&A
- What is Edity Therapeutics' core technology?
- Edity Therapeutics is developing a platform that harnesses the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells, aiming to reprogram cells and tissue back to health.
- When was Edity Therapeutics founded and by whom?
- Edity Therapeutics was founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster.
- What significant partnership did Edity Therapeutics announce?
- In January 2024, Edity Therapeutics entered into a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach using its proprietary delivery platform.
- Which investors participated in Edity Therapeutics' October 2023 funding round?
- In October 2023, Edity Therapeutics received funding from investors including OurCrowd.
- What is the primary focus of Edity Therapeutics' therapeutic programs?
- Edity Therapeutics is currently working across various indications, including oncology and genetic disease, while also developing programs for regeneration and longevity.